<DOC>
	<DOCNO>NCT03003494</DOCNO>
	<brief_summary>The purpose study measure change physical functioning chronic obstructive pulmonary disease ( COPD ) patient treat Spiolto® Respimat® approximately 6 week routine clinical practice .</brief_summary>
	<brief_title>Effectiveness Handling Spiolto® Respimat ® COPD Patients - Italy</brief_title>
	<detailed_description>Purpose :</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Inclusion criterion : 1 . Written inform consent prior participation 2 . Female male patient = 40 year age 3 . Patients diagnose COPD require longacting dual bronchodilation ( LAMA + LABA ) treatment accord approve Spiolto® Respimat® SmPC therapeutic plan reccomandation Exclusion criterion : 1 . Patients contraindication accord Spiolto® Respimat® SmPC 2 . Patients treat LABA/LAMA combination ( free fix dose ) previous 6 month 3 . Patients continue LABAICS treatment additionally treat Spiolto® Respimat® order avoid double dose longacting betaagonists 4 . Patients followup possible enrol site plan study period approx . 6 week 5 . Pregnancy lactation 6 . Patients currently list lung transplantation 7 . Current participation clinical trial noninterventional study drug device</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>